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cense.Abstract Objective: To assess the epidemiological and clinico-pathological features, surgical and
reconstructive techniques, adjuvant treatments and clinical outcome of breast carcinoma in males
(BCM) at the Egyptian National Cancer Institute (NCI).
Patients and methods: Thirty-two males with breast carcinoma presented to NCI between January
2000 and December 2002. They were evaluated by complete history, physical examination, labora-
tory and radiological investigations.
Results: Median age was 59 years. Left sided and retroareolar breast lumps were the commonest
presentations. Grade II tumors positive for hormone receptors were very common. Stage I, II,
III and IV disease were encountered in 6.2%, 34.4%, 34.4% and 25.0% of patients, respectively.
Curative surgery was done in 22 patients; they received adjuvant hormonal therapy, chemotherapy
and radiotherapy in 22, 16 and 10 patients, respectively. Eight metastatic patients were treated with
palliative measures. Surgery was done in 25 patients; the most common procedure was modiﬁed
radical mastectomy (40.6%). Primary closure was feasible in 17 patients (68%), local ﬂaps wereartment of Epidemiology and
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116 M.M. Elshaﬁey et al.needed in 4 cases (16%), while myocutaneous ﬂap was done in 3 cases (12%). The commonest com-
plication was development of seroma (9 cases). The overall survival (OS) at 5 years was 65.4%. The
disease free survival (DFS) at 5 years was 53.9%. Stage and curative surgery signiﬁcantly affected
OS, while type of surgery was the only variable signiﬁcantly affecting DFS.
Conclusion: Male breast carcinoma occurs at older ages than females, usually in advanced stage.
This necessitates directing attention of males and awareness on the prevalence and risk factors
for this disease.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Table 1 Patients’ characteristics.
Characteristics Number (n= 32) Percentage (%)
Age groups
<50 9 28.1
P50 23 71.9
Occupation
Farmer 13 40.6
Not farmer 19 59.4
Geographic area
Metropolitan 18 56.3
Upper Egypt 3 9.4
Lower Egypt 11 34.3
History of bilharziasis
Positive 19 59.4
Negative 13 40.6
Special habits
Nonsmoker 5 15.6
Smoker 27 84.4
Family history
Negative 29 90.7
Positive 3 9.3Introduction
Breast carcinoma in males (BCM) is relatively a rare disease
that accounts for 1% of all breast cancer and less than 1%
of all cancers in men [1–4]. However BCM incidence has in-
creased over the past 25 years [5–7].
The natural history and prognostic factors parallel those of
breast carcinoma in females (BCF). The differences are older
age at presentation, higher rate of estrogen receptor positivity
(90% vs. 60%, approximately), different distribution of histo-
logical subtypes with more preponderance of the ductal histol-
ogy in males and higher stage at presentation [5,8].
The aim of this retrospective study was to assess the clinico-
pathological features of BCM at the Egyptian National Cancer
Institute (NCI) and to review different surgical treatments and
reconstructive techniques, the role of adjuvant treatments, and
the clinical outcome.
Patients and methods
From January 2000 to December 2002, 32 male patients with
breast carcinoma presented to the NCI, 24 patients of them
(75%) had loco-regional disease while 8 patients (25%) pre-
sented with metastatic disease. All patients under-went full lab-
oratory investigations, chest radiography, and abdominal
ultrasound. Bone scan was done when indicated (large tumors,
positive nodes or suspected bone metastases). Pathological
diagnosis was obtained by different diagnostic procedures
including incisional biopsy in 14 patients (43.8%), true-cut
needle biopsy in 8 patients (25.0%), excisional biopsy in 3 pa-
tients (9.3%), ﬁne needle aspiration cytology in 2 patients
(6.3%) and frozen section in 5 patients (15.6%). The epidemi-
ological factors studied were patients’ demographic character-
istics, family history, presentation, stage at diagnosis,
investigations, details of treatment, pathology including tumor
size and grade, nodal status and hormone receptor status. All
patients were pathologically staged using the sixth edition of
the AJCC Cancer Staging Manual of Breast cancer criteria
[9]. Overall survival was calculated from the date of patholog-
ical diagnosis to date of death or last follow up. Disease free
survival was calculated from date of surgical intervention to
date of recurrence or death or last follow up. Patients were fol-
lowed up to the end of December 2010.
Statistical methods
Data was analyzed using SPSS win statistical package version
15. Quantitative data were presented as median and range.
Qualitative data were expressed as frequency and percentage.Survival analysis was done using Kaplan-Meier method and
presented as cumulative survival rates. Comparison between
two survival curves was done using Log-rank test. A p-value
<0.05 was considered signiﬁcant.
Results
Thirty-two patients with BCM were studied during the afore-
mentioned time period. They represented only 0.89% of all
cases of breast carcinoma who presented to the NCI in the
same period. The median age at diagnosis was 59 years, rang-
ing between 31 and 87 years. Those younger than 50 years
were 28.1%. Thirteen patients (40.6%) were farmers. The
majority of patients were smokers (84.4%). Nineteen patients
(59.4%) had history of bilharziasis. Only 3 patients (9.3%)
had a positive family history in a 1st degree relative female
(Table 1).
Most patients presented by a breast lump (25 cases, 78.1%)
with slight predilection of the lump to the left side (Fig. 1). The
majority of the lumps occupied the retroareolar region
(23 cases, 71.9%) (Table 2). The median delay between com-
plaints and clinical presentations was 11 months (range:
2–37 months). Gynecomastia was present only in 2 cases
(6.3%). Most patients presented with loco-regional disease
and only 8 cases (25.0%) were metastatic at presentation.
Figure 1 Left male breast cancer presenting with breast lump
(scar of biopsy is shown).
Table 2 Tumors’ characteristics.
Item Number (n= 32) Percentage (%)
Symptoms
Breast lump 25 78.1
Breast ulcer 4 12.5
Gynecomastia 2 6.3
Bony aches 1 3.1
Side
Right 13 40.6
Left 19 59.4
Site
Retroareolar 23 71.9
Upper outer quadrant 9 28.1
Grade
II 30 93.8
III 2 6.2
Estrogen receptors (n = 18)a
Positive 15 83.3
Negative 3 16.7
Progesterone receptors (n = 18)a
Positive 14 77.8
Negative 4 22.2
T-stage
T1 2 6.3
T2 14 43.7
T3 4 12.5
T4 12 37.5
N-stage
pN0 11 34.4
pN1 9 28.1
pN2 2 6.2
Unknown 10 31.3
M-stage
M0 24 75.0
M1 8 25.0
TNM staging
I 2 6.3
IIa 4 12.5
IIb 7 21.8
IIIa 2 6.3
IIIb 9 28.1
IV 8 25.0
a Only 18 patients did hormone receptors.
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grade II. The estrogen and progesterone receptor status were
known in 18 patients. Estrogen receptors were positive in
83.3% of cases (15/18) while progesterone receptors were posi-
tive in 77.8% of cases (14/18). Stage I, II, III and IV disease
were encountered in 6.2%, 34.4%, 34.4% and 25.0% of pa-
tients, respectively. The median numbers of the dissected and
positive axillary lymph nodes were 13 and 6, respectively. Cap-
sular invasion was noticed in all cases with positive axillary
lymph nodes. Eight patients (25.0%) had metastatic disease
that affected the bones, lungs and liver in 5, 3 and 2 patients,
respectively. The median time between diagnosis and deﬁnitive
surgical management, was 1 month (range between 0 and
48 months). Modiﬁed radical mastectomy (MRM) was done
in 13 cases (40.6%), radical mastectomy (RM) was done in 9
cases (28.1%) while simple mastectomy was done in 3 patients
(9.4%) presenting with metastases with marked tumor ulcera-
tion and fungation (Table 3). Two patients (6.3%) refused sur-
gical treatment and lost to follow-up (Fig. 2).
Out of the 30 patients whose management data was docu-
mented, hormonal therapy, chemotherapy and radiotherapy
were used in 100%, 73.3%, and 43.3%, respectively. Hor-
monal therapy (tamoxifen) was used as adjuvant to surgery
in 22 cases (73.3%); and as palliative measure in 8 cases
(26.7%). Chemotherapy was used as adjuvant to surgery in
16 cases (53.3%) and as a palliative measure in 6 cases
(20.0%). Anthracycline-containing chemo-therapies (FAC/
FEC) were the most common (18/22; 81.8%). Radiotherapy
was given as adjuvant to surgery in 10 patients (33.3%) and
was palliative in 3 patients. The 8 patients (26.7%) with distant
metastases were treated by palliative hormonal therapy with or
without chemotherapy and radiotherapy (Table 3).
For the 25 cases where mastectomy was done, primary clo-
sure was feasible in 17 cases (68%) (Figs. 3 and 4), local ﬂaps
were needed in 4 cases (16%) while pedicled latissimus dorsi
myocutaneous ﬂap (MCF) was done in 3 (12%) cases
(Fig. 5). In only one patient (4%) with T4 lesion resection of
part of the chest wall (3 ribs) was needed, where reconstruction
was done by bone cement with double prolene mesh covered
by pedicled rectus abdominus myocutaneous ﬂap (Table 3).
The most common complications encountered were the devel-
opment of seroma (9 cases; 36%), followed by partial edgesloughing in 3 cases (12%) (Fig. 4), wound infection in 1
patient (4%) and liver failure in 1 patient (4%).
During the course of this study, local recurrence developed
in 3 patients (13.6%) of those who underwent curative surgery
(22 patients), while distant metastases developed in 7 patients
(31.8%). One patient developed both local recurrence and dis-
tant metastases. After a median follow up of 58 months (range:
1–132 months), 8 patients (25%) were dead of breast cancer,
16 were living free of disease (50%) and six were living with
evidence of disease (19%). Two patients with non-metastatic
disease refused surgery and did not show up again. The cumu-
lative overall survival (OS) for the whole group at 3, 5 and
10 years was 77.9%, 65.4% and 57.2%, respectively. The
cumulative disease free survival (DFS) for the 22 patients
Table 3 Managements.
Management type Number Percentage (%)
Surgery (n = 32)
Modiﬁed radical mastectomy 13 40.6
Radical mastectomy 9 28.1
Simple mastectomy 3 9.4
Just biopsya 7 21.9
Reconstruction following mastectomy (n = 25)b
Primary closure 17 68.0
Local ﬂaps 4 16.0
Pedicled latissimus dorsi myocutaneous ﬂap 3 12.0
Prolene mesh and pedicled rectus
abdominus myocutaneous ﬂap
1 4.0
Hormonal therapy (n = 30)
Adjuvant 22 73.3
Palliative 8 26.7
Chemotherapy (n = 30)
Adjuvant 16 53.3
Palliative 6 20.0
Not given 8 26.7
Radiotherapy (n = 30)
Adjuvant 10 33.3
Palliative 3 10.0
Not given 17 56.7
a Two cases refused surgical management.
b Reconstruction was done only for patients who did mastectomy.
Figure 3 Scar of left MRM, primary closure was done.
Figure 4 Scar of left MRM, secondary sutures of partial ﬂap
sloughing were done.
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70.0% and 53.9% and 53.9%, respectively (Fig. 6).
Age, side, site, stage, lymph node (LN) status and type of
surgery were analyzed to identify the signiﬁcant variables
affecting the overall and disease free 5 year survival
(Tables 4 and 5). As regards the overall 5 years survival, signif-
icant variables were stage (p= 0.007) and curative surgery
(p= 0.011) (Figs. 7 and 8). There were two factors with bor-
derline signiﬁcance: LN positivity (p= 0.062), and surgery
type with better survival with MRM (p= 0.185).
Regarding disease free survival, surgery type (Fig. 9) was
the only variable signiﬁcantly affecting survival (p= 0.002),
and stage has a borderline signiﬁcant effect (p= 0.123).Figure 2 Left male breast cancer presenting with gynecomastia.
Figure 5 Post mastectomy closure of the skin defect by pedicled
latissimus dorsi myocutaneous ﬂap.
Figure 6 Postoperative specimen, part of the pectoralis major
muscle underneath the tumor was taken as safety margin.
Table 5 The cumulative disease free survival (DFS) at 5 years
in relation to different prognostic factors.
n Cumulative
DFS at
5 years (%)
p-Value
Whole group 22 53.9
Age (years)
<50 9 50.0 0.788
P50 13 57.1
Side
Right 10 44.4 0.407
Left 12 61.9
Site
Retroareolar 13 48.6 0.279
Upper outer quadrant 9 62.5
Stage
Stage I, II 13 64.2 0.123
Stage III 9 38.9
Lymph node status
Positive 11 63.6 0.286
Negative 11 40.5
Type of radical surgery
RM 9 16.7 0.002
MRM 13 69.6
RM= radical mastectomy, MRM=modiﬁed radical
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Breast carcinoma in males (BCM) is relatively a rare disease
that accounts for 1% of all breast cancer and less than 1%
of all cancers in men [1–4]. The global distribution of BCMTable 4 The cumulative overall survival at 5 years in relation
to different prognostic factors.
n Cumulative
overall
survival at
5 years (%)
p-Value
Whole group 30 65.4
Age (years)
<50 9 56.3 0.710
P50 21 70.3
Side
Right 12 58.3 0.862
Left 18 71.3
Site
Retroareolar 21 58.8 0.477
Upper outer quadrant 9 77.8
Stage
Stage I, II 13 91.7 0.007
Stage III, IV 17 39.9
Surgery
Curative 22 76.5 0.011
Not-curative 8 38.1
Lymph node statusa
Positive 11 62.5 0.062
Negative 11 90.9
Type of surgerya
RM 9 57.1 0.185
MRM 13 91.7
RM= radical mastectomy, MRM=modiﬁed radical
mastectomy.
a Only for the 22 cases who underwent curative surgery.
mastectomy.
Figure 7 Overall survival according to stage of BCM.is similar to that of BCF (i.e. BCM is very rare in areas with
a low incidence of breast cancer in general), with few
exceptions. It was reported in the past that BCM is common
in Egypt, an area of relatively low BCF incidence, probably be-
cause of high rates of schistosomiasis-related liver diseases [10].
In our study BCM represented only 0.89% of all breast carci-
nomas presenting to our institute in the same matched period.
Figure 8 Overall survival according to type of treatment in
BCM.
Figure 9 Disease free survival according to type of surgery in
BCM.
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where BCM represented 9.5% and 6.4% of all breast carcino-
mas [11,12]. In a combined 3 Egyptian hospital materials
including (Kasr El Aini hospital, Cairo, Government hospital,
Alexandria and Faculty of Medicine hospital, Alexandria)
BCM represented 6.4% in a total of 706 cases of breast carci-
noma [12]. The authors in these earlier studies suggested hyp-
erestrogenism of the liver caused by bilharziasis as one possible
explanation of the relatively high frequency of BCM in these
early reports. Compared to earlier studies, the low frequency
of BCM in our study may be attributed to the effective preven-
tion and early treatment of bilharziasis in Egypt.The median age of BCM at diagnosis is 68 years; however,
the disease has been reported in males ranging from 5 to
93 years. The greatest incidence occurs 5–10 years later in
males than in females with the vast majority of cases occurring
in the ﬁfth and sixth decades [5,8,13]. The annual incidence of
BCM increases steadily lacking the premenopausal peak seen
in females [2]. In our study the median age of BCM was
59 years while the median age of BCF presenting in the same
period was 49 years.
Factors associated with the development of BCM
include conditions of relative hyperestrogenism [14], testicular
dysfunction due to chromosomal abnormality such as
Klinefelter’s syndrome [15] or environmental factors such as
chronic heat exposure [16] and previous chest wall irradiation
especially in childhood malignancies [17]. In our study 19 cases
had positive past history of bilharziasis which may be a risk
factor attributed to possible associated bilharzial liver ﬁbrosis.
Approximately 30% of BCM have positive family history
of BCM or BCF [1]. Breast cancer in a ﬁrst-degree relative
was reported in 14% in one series [18]. Most cases of BCM
are sporadic but a familial form exists in which both males
and females show an increased risk of developing breast cancer
[10]. In men, BRCA-1 does not appear to be associated with a
signiﬁcantly increased risk of breast cancer. However men with
BRCA-2 mutations are predisposed to breast cancer [19]. In
our study only 3 cases had positive family history of BCF in
ﬁrst degree relatives.
For men, the overall risk of BCM among BRCA-2 muta-
tion carriers is 6%. However in females the implications of dis-
covering a BRCA-2 mutation are much greater because such
mutations confer on these persons a 56–87% BCF risk by
age 70 [20]. Dı´ez and colleagues [19] insisted that all new cases
of BCM should be regarded as being possibly inherited and
should be fully investigated especially if potential transmis-
sions of BRCA-2 mutations to female offspring are involved.
Almost 85% of BCM present with a unilateral slightly
irregular ﬁrm, painless or minimally tender, subareolar mass
often eccentric with rare nipple involvement and there is a
slight predilection for left breast with a ratio of left to right
of 1.07:1 [21,22]. In the present study, most cases presented
with breast lump (78.1%) with a slight predilection to the left
side (59.4%). Seventy-two percent of cases were in the retro-
areolar region. Breast cancer tends to present at later stages
in males than in females [5,6,13,23].
In this study, the mean delay between complaint and pre-
sentation was 11.5 months, which resulted in advanced stage
at presentation (11 cases with stage III, and 8 cases with stage
IV). Great attention and awareness for the males on the prev-
alence and risk factors for this disease should be taken to
achieve early detection of these cases. Also males with breast
carcinoma require proper psychological support [6,15].
Although open biopsy was considered the gold standard for
the evaluation of BCM, nowadays the non-operative evalua-
tion of breast masses in BCM can employ either cytology
(FNA) or core biopsy, depending on different institutions
experience [24]. In our study, pathological diagnosis by open
biopsy was done in 22 cases of which 15 cases were already
done outside our institute which is considered a tertiary center
in Egypt.
Approximately 90% of all breast tumors in men are inva-
sive carcinomas, the remaining 10% are non-invasive. Eighty
percent of all tumors are inﬁltrating duct carcinoma as normal
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lobules; lobular carcinoma is much less common than in fe-
males and represents only 1% of cases. Non-invasive carcino-
mas in men are low to intermediate grade ductal carcinoma
in situ (DCIS) whereas; pure lobular CIS is extremely rare
[25,26]. Histopathological examination of tumors in our study
revealed that all cases (100%) were invasive ductal carcinoma,
and almost all cases were of intermediate grade (grade II).
Most cases of BCM are ER positive (65–94%) compared to
60% in women therefore, most of patients will be treated with
tamoxifen or will respond to hormonal manipulation than with
female patients. Similarly, BCM is more commonly PR posi-
tive (93%) [27]. The present series conﬁrmed the high preva-
lence of ER positivity in male breast cancer patients (83.3%).
Surgical excision is the mainstay treatment for BCM.
Although radical mastectomy was traditionally the treatment
of choice because of the paucity of male breast tissue and
the resultant proximity of these lesions to chest wall, surgical
therapy has evolved towards more limited procedures. A 30-
year review of 170 cases treated at the National Cancer Insti-
tute of Italy in Milan noted a trend from RM to MRM and
ﬁnally total mastectomy TM for (smaller and DCIS lesions)
in the later period of study [28]. A similar surgical trend was
noted in the United States [18]. In the present study, the major-
ity of cases were treated by MRM (13 cases); RM was done in
(9 cases), while simple mastectomy was done in three meta-
static patients with marked tumor ulceration and fungation.
Most of these cases were closed primarily after mastectomy
(17 cases). In 8 cases reconstruction by ﬂaps was needed. Local
skin ﬂaps were done in 4 cases while pedicled latissimus dorsi
myocutaneous ﬂap was done in 3 cases. Pedicled rectus abdo-
minus myocutaneous ﬂap with bone cement and double pro-
lene mesh was done in only one case with chest wall defect
after mastectomy in T4 lesion.
Tamoxifen is accepted as ﬁrst-line adjuvant therapy for
receptor-positive BCM and is often used alone [5,15,27,29–
31]. Because BCM is a rare disease, there are no large random-
ized trials that support the use of adjuvant chemotherapy or
trastuzumab. However, given the conﬁrmed results regarding
BCF and the positive experiences in men, both men and wo-
men could share the same guidelines for adjuvant treatment.
Chemotherapy is proposed in young men with axillary nodal
involvement and/or negative hormone receptors [30,31]. De-
spite adjuvant radiotherapy (RT) appears to reduce loco-regio-
nal recurrences, survival beneﬁt is unknown. Men may have
higher risk of internal mammary nodal disease and thus could
theoretically beneﬁt from internal mammary radiation
[5,30,32]. In our study, tamoxifen was given either postopera-
tively as an adjuvant therapy to all operable cases, or to met-
astatic cases as a palliative therapy. Chemotherapy was given
as adjuvant treatment in 16 patients and as palliative treatment
in 6 cases, while radiation therapy was given as adjuvant treat-
ment in 10 cases, and as palliative treatment in 3 cases.
The most signiﬁcant prognostic factors for BCM are stage,
tumor size and lymph node status. Hultborn et al. [33] demon-
strated that age, tumor size, and lymph node status were the
most signiﬁcant prognostic factors by multivariate analysis
among a group of 166 BCM patients. As in women, axillary
lymph node status, tumor site, histological grade and hormone
receptor status are the most signiﬁcant prognostic factors in
men with breast cancer. However nodal disease is the most
important negative prognostic factor. The clinical outcomefor men is similar to that for women. The 5-year overall sur-
vival rates for all stages range from 36 to 66 [10].
In our study, as regards the overall 5 years survival, the
only signiﬁcant variables were stage (p= 0.007) and curative
surgery (p= 0.011). There were two factors with borderline
signiﬁcance: LN positivity (p= 0.062), with better survival
with negative LN cases, and surgery type with better survival
with MRM (p= 0.186). The latter is explained by the fact that
RM was usually done for more locally advanced disease.
Regarding disease free survival, surgery type was the only var-
iable signiﬁcantly affecting survival (p= 0.002), and stage has
a borderline signiﬁcant effect (p= 0.123).
Conclusion
Breast carcinoma in Egyptian males occurs at older ages than
females. The proportion of BCM to BCF is much less than
older series 50–70 years ago. There is always a delay in the
male patients since the ﬁrst complaint until they seek medical
advice, which results in an advanced disease at presentation.
This should be looked after with great concern mainly by
directing the attention of males and increasing their awareness
on the prevalence and risk factors for this disease. For men
who present with non-metastatic disease the recommended
surgical therapy is modiﬁed radical mastectomy. The majority
of our cases of BCM were hormone-receptor positive and
tamoxifen plays an important role in most patients.References
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